Suppr超能文献

儿童三种现实世界中弱视治疗方法的前瞻性观察研究:临床结果和预测因素。

Prospective observational study of three real-world amblyopia treatments in children: clinical outcomes and predictive factors.

作者信息

Xu Ke, Wang Litao, Bi Chao

机构信息

Department of Ophthalmology, Xishuangbanna Dai Autonomous Prefecture People's Hospital, Jinghong, Yunnan, 666100, China.

Department of ophthalmology, Jinan Second People's Hospital, 148 Jingyi Road, Jinan, Shandong, 250000, China.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2025 Jul 31. doi: 10.1007/s00417-025-06913-7.

Abstract

BACKGROUND

Amblyopia is a leading cause of reduced visual acuity in children. While patching alone remains standard care, combining patching with atropine or visual stimulation may yield superior outcomes. This prospective observational study aimed to (1) compare the effectiveness of three real-world amblyopia treatments-patching alone, patching plus atropine, and patching plus visual stimulation-and (2) identify factors predictive of successful visual outcomes.

METHODS

A total of 283 children (mean age 6.9 ± 2.3 years) with clinically diagnosed amblyopia were enrolled at a single center in China and followed for 12 months. Treatment selection was based on routine clinical practice and parent/physician preference. Best-corrected visual acuity (VA) in logMAR and stereopsis (arc seconds) were measured at baseline, 3, 6, and 12 months. Adherence was monitored via diaries/interviews, and adverse events were documented. Multivariable logistic regression examined predictive factors for successful outcome, defined as final VA ≤ 0.3 logMAR and stereopsis ≤ 40 arc seconds.

RESULTS

Of the 283 enrolled children, 95 received patching alone, 90 underwent patching plus atropine, and 98 received patching plus visual stimulation; baseline characteristics were similar among groups (p > 0.05). By 12 months, mean logMAR VA improved from 0.55 ± 0.11 to 0.33 ± 0.07 (patching alone), 0.56 ± 0.10 to 0.26 ± 0.05 (patching + atropine), and 0.54 ± 0.12 to 0.22 ± 0.05 (patching + visual stimulation) (p < 0.01), while stereopsis (seconds of arc) improved from 59 ± 7 to 40 ± 6, 60 ± 8 to 32 ± 5, and 58 ± 8 to 28 ± 5, respectively (p < 0.01). Photophobia (10.0%) and blurred near vision (7.8%) were reported only in the atropine group, and overall adherence (≥ 80% patching hours) ranged from 58.9% in the atropine group to 67.3% in the visual stimulation group. Multivariable analysis showed that receiving patching + atropine (OR = 2.10, 95% CI 1.25-3.52) or patching + visual stimulation (OR = 3.65, 95% CI 2.05-6.48), along with better baseline VA (OR = 0.75, 95% CI 0.62-0.89, per 0.1 logMAR), and ≥ 80% adherence (OR = 2.42, 95% CI 1.56-3.76), significantly increased the odds of achieving successful final outcomes (p < 0.01 for all).

CONCLUSION

Combining patching with atropine or visual stimulation led to greater improvements in both VA and stereopsis compared to patching alone, with high adherence and better baseline VA serving as strong predictors of success.

摘要

背景

弱视是导致儿童视力下降的主要原因。虽然单纯遮盖疗法仍是标准治疗方法,但将遮盖与阿托品或视觉刺激相结合可能会产生更好的效果。这项前瞻性观察性研究旨在:(1)比较三种现实世界中弱视治疗方法——单纯遮盖、遮盖加阿托品、遮盖加视觉刺激——的有效性;(2)确定预测视觉治疗成功的因素。

方法

在中国的一个单一中心,共纳入283名临床诊断为弱视的儿童(平均年龄6.9±2.3岁),并随访12个月。治疗方法的选择基于常规临床实践以及家长/医生的偏好。在基线、3个月、6个月和12个月时测量最佳矫正视力(VA,以logMAR表示)和立体视(弧秒)。通过日记/访谈监测依从性,并记录不良事件。多变量逻辑回归分析确定预测治疗成功的因素,治疗成功定义为最终VA≤0.3 logMAR且立体视≤40弧秒。

结果

在283名纳入研究的儿童中,95名接受单纯遮盖治疗,90名接受遮盖加阿托品治疗,98名接受遮盖加视觉刺激治疗;各组基线特征相似(p>0.05)。到12个月时,单纯遮盖组的平均logMAR VA从0.55±0.11提高到0.33±0.07,遮盖加阿托品组从0.56±0.10提高到0.26±0.05,遮盖加视觉刺激组从0.54±0.12提高到0.22±0.05(p<0.01);立体视(弧秒)分别从59±7提高到40±6、60±8提高到32±5、58±8提高到28±5(p<0.01)。畏光(10.0%)和近视力模糊(7.8%)仅在阿托品组中出现,总体依从性(≥80%的遮盖时间)从阿托品组的58.9%到视觉刺激组的67.3%不等。多变量分析显示,接受遮盖加阿托品治疗(OR=2.10,95%CI 1.25-3.52)或遮盖加视觉刺激治疗(OR=3.65,95%CI 2.05-6.48),以及更好的基线视力(OR=0.75,95%CI 0.62-0.89,每0.1 logMAR)和≥80%的依从性(OR=2.42,95%CI 1.56-3.76),显著增加了最终治疗成功的几率(所有p<0.01)。

结论

与单纯遮盖相比,遮盖联合阿托品或视觉刺激在VA和立体视方面均有更大改善,高依从性和更好的基线视力是治疗成功的有力预测因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验